ArticleJournal of clinical practice and research2024
Neuroprotective Effects of
Article in Journal of clinical practice and research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Zingerone as a neuroprotective agent in experimental diabetes: evidence from oxidative stress, inflammatory, and apoptotic markers.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Antioxidant and Neuroprotective Potential of Some Edible Fruits and Vegetable Extracts Based on Comparative Phytochemical Profiling and Bioactivity.Plants (Basel, Switzerland) · 2026Article
- Integrating clinical evidence with natural product therapies for elderly-onset type 2 diabetes.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Exploring novel therapeutic approaches for diabetic neuropathy (DN) is crucial, and Materials and Methods: Adult male Wistar rats were randomly assigned to control, untreated diabetic, and FCSO-treated diabetic groups. Diabetes was induced by a single intraperitoneal injection of streptozotocin (STZ) at a dose of 50 mg/kg, confirmed by hyperglycemia (>250 mg/dL). The treatment group received FCSO orally at a dose of 4 mL/kg/day for 5 weeks. Blood glucose was monitored at the initiation and conclusion of the treatment, while insulin and glycated hemoglobin (HbA1c) were assessed at the study's endpoint. The hot plate test was conducted at the 3 Results: Diabetes resulted in elevated blood glucose and HbA1c levels, along with decreased insulin levels, indicative of diabetic conditions. Increased oxidative stress and inflammation were observed, alongside reductions in nociceptive response and nerve conduction velocity, indicating DN progression. However, FCSO treatment mitigated these effects, restoring markers to levels comparable to those of normal controls. Conclusion: Early intervention with FCSO appears to counteract the mechanisms leading to DN, exerting neuroprotective and preventive effects. These findings underscore the therapeutic potential of FCSO and highlights its role as a promising treatment against DN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.